EVA summary	(Etana)
Teva Pharmaceuticals (ADR Israel) develops, manufactures and markets generic and proprietary branded drugs. 85% of sales from North America and Europe.

Recommendation: I do not recommend BUY, though it is in the buy range.
Put on watchlist, high quality co. but the competition bothers me. That said, I think this is a strong company that will grow sales, earnings, price. And generic drugs is fast growing market.

Positives:
1. The trend is towards generic drugs and TEVA has benefited greatly
2. From ValueLine: 
   a. 7/17: eps 1c ahead of estimate; 
   b. sizable expansion potential: "generic drug growth opportunities abound"
   c. timely short and long term
   d. acquired BARR
   e. High est sales & eps growth (12%) rates for a lge company
   f. projects high price 95-130 
3. From ManifestInvesting
   a.yes Blue 87% green 15.2%
   b. CAPS 4 star

Negatives:
1 narrow moat
2. 24% debt (probably from acquisition)
3. large sized company (revenue $12B)
4. CR ratio 1:1 (should be 2:1) (assets - inventory) /liability
5. Morningstar *** consider buying at $41 (overvalued)
6. Competition was closing in until the recent BARR acquisition
3. From ManifestInvesting only projects $101 high price

SSG summary:
1. Graph:
a.  Sales and profitabity up straight & parallel at historical 28%
b .  Earnings flat past 2 years (competition); profitibility growing faster than earnings? efficient?
c.  cash flow down this year due to acquisition, but still plenty of cash
2. s2A slightly down but really flat and high margins 25%
3. 2B down due to recent acquisition
4. 4A: Est high P/E 22.6 x est high eps $5.13 = Est future high price $116 (MI $101; VL 95-130)
5. Projected low price 34.2 (I used forecast low price since it was low #)
6. RV 108% a bit high (as per Morningstar)
7. 3.8 Gain : risk ratio good
8. 18.5% Total return (Excellent!)